Novo Nordisk shortens its name to Novo ahead of London strategy day

14 September 2026

Danish pharma major Novo Nordisk (NOV: N) said on Monday it will use the single name "Novo" in day-to-day communications, part of a rebrand built around the line "Lasting Health Starts Now" and a new set of company principles called "The Novo Way."

Novo Nordisk A/S remains the legal name worldwide. The updated visual identity retains the Apis bull, the emblem drawn from the company's heritage, in a modernized form. The company said the aim is a more recognizable presence across medicines, partnerships, marketing and stakeholder engagement.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical